Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.
Jeffrey CrawfordNeelima DenduluriDebra PattXiaolong JiaoPhuong Khanh MorrowJacob GarciaRichard BarronGary H LymanPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2019)
Dose delays, dose reductions, and reduced RDI were common, and dose delays ≥ 7 days and high RDI were significantly associated with decreased mortality. These results can help identify potential risk factors and characterize the effect of chemotherapy dose modification strategies on mortality.